Perrigo Co. (Nasdaq: PRGO) Monday announced that it has begun shipments of Guaifenesin 600mg Extended-Release tablets in a launch to its retail and wholesale customers
Perrigo Co. (Nasdaq: PRGO) Thursday announced that its board of directors declared a quarterly dividend of 9 cents a share.
The Michigan Strategic Fund Wednesday approved state incentives to support 14 business expansions that are expected to generate more than $1.1 billion in investments and add 4,590 jobs in Michigan.
The Perrigo Company (Nasdaq: PRGO) announced that it has begun shipments of over-the-counter nicotine polacrilex mini lozenge USP, 2 mg (mint flavor) and 4 mg (mint flavor).
Perrigo Co. Tuesday announced that it has begun commercial shipments of betamethasone valerate foam 0.12%, the generic equivalent of Luxiq Foam, consistent with the date certain launch settlement previously announced.
Allegan-based Perrigo Co. announced that it has made initial shipments distributing Cumberland Pharmaceuticals Inc.’s authorized generic form of Acetadote (acetylcysteine) injection, and that it had received FDA clearance to manufacture new infant formula products.
The latest staffing, leadership and boardroom news from Michigan’s technology-focused companies, institutions and groups
The generic drug and over-the-counter health product manufacturer Perrigo Co. (Nasdaq: PRGO) announced that it has agreed to settle its Hatch-Waxman litigation relating to Acetadote (acetylcysteine) injection brought by Cumberland Pharmaceuticals Inc.
Perrigo Co. (Nasdaq: PRGO) Monday announced that it has closed the acquisition of Sergeant’s Pet Care Products Inc., a privately-held, Omaha, Neb.-based manufacturer of over-the-counter companion animal healthcare products, for approximately $285 million in cash.
The generic drug and store-brand health and beauty products maker Perrigo Co. (Nasdaq: PRGO) Thursday reported net income fo $393 million or $4.18 a share in its fiscal year ended June 30, up 15 percent from $340.6 million or $3.64 a share in the prior fiscal year.